Literature Review

MRI May Reveal PML in Patients With Undetectable JCV


 

MRI Alone Cannot Yet Support Diagnosis

“Dr. Wijburg and colleagues raise an important point in our understanding of the development of PML by showing that small brain lesions may be present at what may be the start of JCV infection when the virus is still undetectable in CSF,” said Eugene O. Major, PhD, a consultant in the Division of Neuroimmunology and Neurovirology at NINDS in Bethesda, Maryland, in an accompanying editorial. “However, it is not yet clear how well the relationship between viral load in CSF and MRI brain lesions approximates the stages of the disease and the processes with which it affects its target brain cells.”

Repeat testing may be worthwhile when CSF testing is negative, because some patients test positive weeks after testing negative, he added. “Suspicion for PML may be increased when MRI shows signs of PML despite negative CSF testing, but it is too early to rely on MRI alone for diagnosis.”

Dr. Major has received consulting fees while serving on independent adjudication committees for Takeda/Millennium, Roche/Genentech, and GlaxoSmithKline.He has patent rights at the NIH as coinventor of the Ultrasensitive Quantitative PCR Multiplex assay for the detection of JCV DNA–distinguishing viral variants.

—Nicola Garrett

Suggested Reading

Major EO. Progressive multifocal leukoencephalopathy lesions and JC virus: the limits and value of imaging. JAMA Neurol. 2018 Mar 12 [Epub ahead of print].

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al. Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 2018 Mar 12 [Epub ahead of print].

Pages

Recommended Reading

Siponimod May Benefit Patients With Secondary Progressive MS
MDedge Neurology
Ari Green, MD
MDedge Neurology
MRI Techniques Could Help Distinguish Between MS and Migraine
MDedge Neurology
Updates in MS: Highlights From the ECTRIMS and ACTRIMS Annual Meetings
MDedge Neurology
Rare, serious alemtuzumab adverse events emerge
MDedge Neurology
Multiple sclerosis “top picks” from AAN 2018
MDedge Neurology
Blood-brain barrier health may signal early loss of MS treatment response
MDedge Neurology
Eating Fish May Be Associated With a Reduced Risk of MS
MDedge Neurology
VIDEO: AAN MS guidelines aim to help clinicians weigh expanding drug choices
MDedge Neurology
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
MDedge Neurology